COVID-19
Hydroxychloroquine: small effects in mild disease
COVID-19
"一个涉及150个新冠肺炎患者的随机双盲临床试验的结果出来了，与对照组相比，使用羟基氯喹的患者的治疗结果和病毒量都没有差异，反而有严重副作用。"
Hydroxychloroquine: small effects in mild disease
Nature Reviews Immunology (2020)Cite this article
This preprint reports a double-blind, randomized clinical trial of 62 patients to assess the efficacy of hydroxychloroquine (HCQ) in mild COVID-19. Patients in the treatment arm received 400 mg HCQ per day for 5 days. Fever and cough resolved on average 1 day earlier with HCQ, although the distribution of symptomatic patients at day 0 was not even between groups. No patients receiving HCQ progressed to severe disease, whereas 4 of 31 patients in the control arm progressed. Few clinical data and no viral load measurements were reported, limiting the conclusions that can be drawn from this trial. This study suggests relative efficacy for patients with mild disease and warrants larger clinical trials, but the effects of HCQ on patients with more severe COVID-19 remain unknown.
References
Original article
Chen, Z. et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Preprint at medRxiv https://doi.org/10.1101/2020.03.22.20040758 (2020)- Article
- Google Scholar
Author information
Affiliations
- Sinai Immunology Review Project, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Rachel Levantovsky
- & Nicolas Vabret
Corresponding authors
Correspondence to Rachel Levantovsky or Nicolas Vabret.[/p][p]
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
Reprints and Permissions
Cite this article
Levantovsky, R., Vabret, N. Hydroxychloroquine: small effects in mild disease. Nat Rev Immunol (2020). https://doi.org/10.1038/s41577-020-0315-4
Download citation
https://www.nature.com/articles/s41577-020-0315-4
一键同布到我集网·各家微博
